Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$15.00
$14.97
$3.06
$15.00
$521.45M1601,442 shs247,800 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$3.94
-1.1%
$3.83
$1.75
$10.00
$271.31M0.58827,273 shs313,955 shs
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$0.04
-2.6%
$0.03
$0.02
$0.06
$6.99M0.6247,223 shs39,340 shs
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$2.01
$1.93
$1.15
$42.20
$97.10M-2.042.93 million shs468,006 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+3.11%-3.40%-1.24%+33.11%+123.60%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
+14.20%-2.83%+53.66%+19.62%-31.40%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
+8.65%+8.65%-5.63%+58.27%-82.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.5079 of 5 stars
3.51.00.00.01.63.30.6
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
4.187 of 5 stars
3.33.00.04.72.40.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.00
N/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.00
Buy$15.00281.19% Upside
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.00
N/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.50
Moderate Buy$54.502,611.44% Upside

Current Analyst Ratings Breakdown

Latest SAVA, CVSI, CRVS, and AVEO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$12.00 ➝ $11.00
5/9/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$42.29M12.33N/AN/A$1.33 per share11.28
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.51 per shareN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$15.70M0.43N/AN/A$0.01 per share3.68
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)
CV Sciences, Inc. stock logo
CVSI
CV Sciences
-$2.39MN/A0.00N/A-12.25%-89.43%-22.75%N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/6/2025 (Estimated)

Latest SAVA, CVSI, CRVS, and AVEO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
5/8/2025Q1 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.48N/A-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.94
2.37
2.35
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
4.90
4.90
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.26
1.14
0.30
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
9.08
9.08

Institutional Ownership

CompanyInstitutional Ownership
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
49.95%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%

Insider Ownership

CompanyInsider Ownership
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
3.29%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
28.50%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
3.80%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
11434.76 million33.62 millionOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million48.74 millionOptionable
CV Sciences, Inc. stock logo
CVSI
CV Sciences
70184.79 million177.77 millionNot Optionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million47.15 millionOptionable

Recent News About These Companies

SAVA - Cassava Sciences Inc Sustainability - Morningstar
Cassava Sciences Inc.
Cassava takes next step for African AI

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVEO Pharmaceuticals stock logo

AVEO Pharmaceuticals NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$3.94 -0.05 (-1.13%)
Closing price 02:54 PM Eastern
Extended Trading
$3.96 +0.02 (+0.51%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CV Sciences stock logo

CV Sciences OTCMKTS:CVSI

$0.04 0.00 (-2.65%)
As of 12:42 PM Eastern

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$2.01 0.00 (0.00%)
Closing price 03:57 PM Eastern
Extended Trading
$2.01 0.00 (0.00%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.